BG62656B1 - Рекомбинантни антитела за хуманната медицина - Google Patents

Рекомбинантни антитела за хуманната медицина Download PDF

Info

Publication number: BG62656B1
Authority: BG; Bulgaria
Prior art keywords: antibody; human; monkey; antigen; region
Prior art date: 1991-07-25

Application number

BG98411A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG98411A (bg

Inventor

Roland A. Newman

Nabil Hanna

Ronald W. Raab

Original Assignee

Idec Pharmaceuticals Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-07-25

Filing date

1994-01-24

Publication date

2000-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27112830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG62656(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-01-24 Application filed by Idec Pharmaceuticals Corporation filed Critical Idec Pharmaceuticals Corporation

1995-02-28 Publication of BG98411A publication Critical patent/BG98411A/bg

2000-04-28 Publication of BG62656B1 publication Critical patent/BG62656B1/bg

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BG98411A 1991-07-25 1994-01-24 Рекомбинантни антитела за хуманната медицина BG62656B1 (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73506491A	1991-07-25	1991-07-25
US85628192A	1992-03-23	1992-03-23
PCT/US1992/006194 WO1993002108A1 (en)	1991-07-25	1992-07-24	Recombinant antibodies for human therapy

Publications (2)

Publication Number	Publication Date
BG98411A BG98411A (bg)	1995-02-28
BG62656B1 true BG62656B1 (bg)	2000-04-28

Family

ID=27112830

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG98411A BG62656B1 (bg)	1991-07-25	1994-01-24	Рекомбинантни антитела за хуманната медицина

Country Status (24)

Country	Link
EP (3)	EP1715045A3 (no)
JP (1)	JP3048640B2 (no)
KR (1)	KR0137806B1 (no)
AP (1)	AP307A (no)
AT (2)	ATE327331T1 (no)
AU (1)	AU673499B2 (no)
BG (1)	BG62656B1 (no)
BR (1)	BR9206313A (no)
CA (1)	CA2114015C (no)
CZ (1)	CZ289472B6 (no)
DE (2)	DE69233011T2 (no)
DK (2)	DK1266965T3 (no)
ES (2)	ES2196002T3 (no)
FI (1)	FI117703B (no)
HU (2)	HUT70272A (no)
IL (1)	IL102640A0 (no)
MY (1)	MY121185A (no)
NO (1)	NO318097B1 (no)
NZ (1)	NZ243706A (no)
OA (1)	OA09879A (no)
PT (1)	PT100735B (no)
RO (1)	RO116404B1 (no)
SK (2)	SK285960B6 (no)
WO (1)	WO1993002108A1 (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991002078A1 (en)	1989-08-07	1991-02-21	Peptide Technology Ltd	Tumour necrosis factor binding ligands
US20030225254A1 (en)	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5919452A (en) *	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
JP3502093B2 (ja) *	1991-07-15	2004-03-02	ザ・ウエルカム・ファウンデーション・リミテッド	抗体の製造
US6136310A (en)	1991-07-25	2000-10-24	Idec Pharmaceuticals Corporation	Recombinant anti-CD4 antibodies for human therapy
US7744877B2 (en)	1992-11-13	2010-06-29	Biogen Idec Inc.	Expression and use of anti-CD20 Antibodies
DE69303494T2 (de)	1992-11-13	1997-01-16	Idec Pharma Corp	Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5733742A (en)	1993-06-03	1998-03-31	Therapeutic Antibodies Inc.	Production of antibody fragments from whole blood
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
ES2151054T3 (es) *	1994-04-26	2000-12-16	Kanebo Ltd	Farmaco para el tratamiento de la artritis reumatoide.
KR20040058016A (ko) *	1994-10-25	2004-07-02	글락소 그룹 리미티드	Ｃｄ23에 대한 결합제
JP2001506122A (ja) *	1994-12-07	2001-05-15	エフ．ホフマン−ラロシュアーゲー	免疫抑制作用を有するモノクローナル抗体断片
US7153508B2 (en)	1995-06-07	2006-12-26	Biogen Idec Inc.	Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en)	1995-06-07	2007-02-13	Biogen Idec Inc.	Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en)	1995-06-07	2000-09-05	Idec Pharmaceuticals Corporation	Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
US6893636B2 (en)	1997-02-20	2005-05-17	Biogen Idec Ma Inc.	Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6011138A (en) *	1997-02-20	2000-01-04	Idec Pharmaceuticals Corporation	Gamma-1 anti-human CD23 monoclonal antibodies
US7033589B1 (en)	1997-02-20	2006-04-25	Biogen Idec Ma Inc.	γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
ES2230848T3 (es) *	1998-04-28	2005-05-01	Smithkline Beecham Corporation	Anticuerpos monoclonales con inmunogenicidad reducida.
GB9809839D0 (en)	1998-05-09	1998-07-08	Glaxo Group Ltd	Antibody
CN101695574A (zh)	1998-08-11	2010-04-21	拜奥根Idec公司	包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
BR9915164A (pt)	1998-11-09	2003-01-07	Idec Pharma Corp	Tratamento de malignidades hematológicas associadas com células de tumor circulantes usando anticorpo anti-cd20 quimérico
NZ514914A (en)	1999-05-07	2004-09-24	Genentech Inc	Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US8557244B1 (en)	1999-08-11	2013-10-15	Biogen Idec Inc.	Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
JP4762478B2 (ja)	2000-07-03	2011-08-31	キャタレントファーマソリューションズリミテッドライアビリティカンパニー	発現ベクター
AU2001271614B2 (en) *	2000-07-03	2007-05-31	Catalent Pharma Solutions, Llc	Host cells containing multiple integrating vectors
EP1299556A2 (en) *	2000-07-03	2003-04-09	Gala Design, Inc.	Host cells containing multiple integrating vectors
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20050101012A1 (en)	2001-03-12	2005-05-12	Gerold Schuler	CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (en) *	2001-03-12	2002-09-18	Gerold Schuler	CD4+CD25+regulatory T cells from human blood
TWI334439B (en)	2001-08-01	2010-12-11	Centocor Inc	Anti-tnf antibodies, compositions, methods and uses
US20040038304A1 (en)	2002-03-28	2004-02-26	Gala Design, Inc.	Antibody libraries
US7384738B2 (en)	2002-03-28	2008-06-10	Bremel Robert D	Retrovirus-based genomic screening
US8222033B2 (en)	2002-08-12	2012-07-17	Argos Therapeutics, Inc.	CD4+CD25− T cells and Tr1-like regulatory T cells
KR20090088973A (ko)	2002-10-17	2009-08-20	젠맵 에이/에스	Ｃｄ20에 대한 인간 모노클로날 항체
JP2007534305A (ja) *	2003-11-07	2007-11-29	アムジェンインコーポレイテッド	サル免疫グロブリン配列
AU2004291107B2 (en)	2003-11-14	2010-09-30	Brigham And Women's Hospital, Inc.	Methods of modulating immunity
NZ550225A (en)	2004-03-30	2010-11-26	Glaxo Group Ltd	Immunoglobulins that bind oncostatin and inhibit or block interaction between hOSM and pg130
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
TWI307630B (en)	2004-07-01	2009-03-21	Glaxo Group Ltd	Immunoglobulins
EP1919504B1 (en) *	2005-08-03	2013-10-16	iBio, Inc.	Antibody to bacillus anthracis protective antigen
MX2008002161A (es) *	2005-08-15	2008-04-22	Arana Therapeutics Ltd	Anticuerpos quimericos con regiones de primate del nuevo mundo.
EP1945668A4 (en) *	2005-08-15	2009-07-22	Arana Therapeutics Ltd	SYNTHETIC ANTIBODIES WITH FRAMEWORK REGIONS OF NEUWELTPRIMATEN
US7981414B2 (en) *	2005-12-20	2011-07-19	Cephalon Australia Pty Ltd	Anti-inflammatory dAb
CN103232540A (zh)	2006-02-01	2013-08-07	赛法隆澳大利亚控股有限公司	结构域抗体构建体
EP2056858B1 (en)	2006-08-11	2014-06-25	CSL Limited	Treatment of pulmonary disease conditions
TW200817438A (en)	2006-08-17	2008-04-16	Hoffmann La Roche	A conjugate of an antibody against CCR5 and an antifusogenic peptide
PL2066349T3 (pl)	2006-09-08	2012-09-28	Medimmune Llc	Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
CA2666682C (en)	2006-10-19	2014-07-08	Merck & Co., Inc.	Anti-il-13r.alpha.1 antibodies and their uses thereof
PL2829551T3 (pl)	2006-10-19	2018-04-30	Csl Limited	Antagonisty przeciwciała o wysokim powinowactwie wobec receptora alfa 1 interleukiny-13
TW200902544A (en)	2007-03-13	2009-01-16	Hoffmann La Roche	Peptide-complement conjugates
US20090022720A1 (en)	2007-07-20	2009-01-22	Stephan Fischer	Conjugate of an antibody against CD4 and antifusogenic peptides
US8637466B2 (en)	2008-08-11	2014-01-28	Nektar Therapeutics	Multi-arm polymeric alkanoate conjugates
US8415291B2 (en)	2008-10-31	2013-04-09	Centocor Ortho Biotech Inc.	Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
GB2476681B (en)	2010-01-04	2012-04-04	Argen X Bv	Humanized camelid VH, VK and VL immunoglobulin domains
TWI689314B (zh)	2010-11-30	2020-04-01	建南德克公司	低親和力血腦障壁受體抗體及其用途
WO2012088445A1 (en)	2010-12-22	2012-06-28	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en)	2010-12-22	2013-12-12	Nektar Therapeutics	Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012166555A1 (en)	2011-05-27	2012-12-06	Nektar Therapeutics	Water - soluble polymer - linked binding moiety and drug compounds
EP2974976A1 (de) *	2011-10-31	2016-01-20	Embella GmbH	Einhändig bedienbare verpackung mit doppellasche
US10940204B2 (en)	2015-07-31	2021-03-09	Research Institute At Nationwide Children's Hospital	Peptides and antibodies for the removal of biofilms
EP3365027B1 (en)	2015-10-14	2022-03-30	Research Institute at Nationwide Children's Hospital	Hu specific antibodies and their use in inhibiting biofilm
US10465003B2 (en)	2016-02-05	2019-11-05	Janssen Biotech, Inc.	Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US12098188B2 (en)	2017-01-04	2024-09-24	Research Institute At Nationwide Children's Hospital	Antibody fragments for the treatment of biofilm-related disorders
AU2018206552B2 (en)	2017-01-04	2024-10-24	Research Institute At Nationwide Children's Hospital	DNABII vaccines and antibodies with enhanced activity
CA3052095A1 (en)	2017-01-30	2018-08-02	Janssen Biotech, Inc.	Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
KR20240038148A (ko)	2017-02-07	2024-03-22	얀센 바이오테크 인코포레이티드	활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3595445B1 (en)	2017-03-15	2024-09-04	The Research Institute at Nationwide Children's Hospital	Composition and methods for disruption of bacterial biofilms without accompanying inflammation
US12161701B2 (en)	2018-10-05	2024-12-10	Research Institute At Nationwide Children's Hospital	Compositions and methods for enzymatic disruption of bacterial biofilms
CN113874073A (zh)	2019-05-23	2021-12-31	詹森生物科技公司	用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
CN119504987A (zh)	2019-07-08	2025-02-25	国家儿童医院研究所	破坏生物膜的抗体组合物
US12258393B2 (en)	2020-05-21	2025-03-25	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
BR112022024745A2 (pt)	2020-06-04	2023-03-07	Bioinvent Int Ab	Melhora de tolerabilidade de anticorpo associada a administração intravenosa
KR20230154315A (ko)	2021-03-09	2023-11-07	바이오인벤트 인터내셔날 에이비	항체의 신규한 조합물 및 이의 용도
EP4482860A1 (en)	2022-02-24	2025-01-01	AbnomX BV	Human-like target-binding proteins
TW202336033A (zh)	2022-03-07	2023-09-16	瑞典商生物創新國際有限公司	抗體之新穎組合及用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3502093B2 (ja) *	1991-07-15	2004-03-02	ザ・ウエルカム・ファウンデーション・リミテッド	抗体の製造

1992
- 1992-07-24 EP EP06010708A patent/EP1715045A3/en not_active Withdrawn
- 1992-07-24 ES ES92917108T patent/ES2196002T3/es not_active Expired - Lifetime
- 1992-07-24 NZ NZ243706A patent/NZ243706A/en unknown
- 1992-07-24 CA CA002114015A patent/CA2114015C/en not_active Expired - Fee Related
- 1992-07-24 CZ CZ1994149A patent/CZ289472B6/cs not_active IP Right Cessation
- 1992-07-24 HU HU9400201A patent/HUT70272A/hu unknown
- 1992-07-24 RO RO94-00095A patent/RO116404B1/ro unknown
- 1992-07-24 JP JP5503072A patent/JP3048640B2/ja not_active Expired - Fee Related
- 1992-07-24 DE DE69233011T patent/DE69233011T2/de not_active Expired - Fee Related
- 1992-07-24 ES ES02012106T patent/ES2265005T3/es not_active Expired - Lifetime
- 1992-07-24 EP EP02012106A patent/EP1266965B1/en not_active Revoked
- 1992-07-24 EP EP92917108A patent/EP0605442B1/en not_active Expired - Lifetime
- 1992-07-24 DE DE69233628T patent/DE69233628T2/de not_active Revoked
- 1992-07-24 AT AT02012106T patent/ATE327331T1/de active
- 1992-07-24 AT AT92917108T patent/ATE237638T1/de not_active IP Right Cessation
- 1992-07-24 DK DK02012106T patent/DK1266965T3/da active
- 1992-07-24 SK SK5059-2005A patent/SK285960B6/sk not_active IP Right Cessation
- 1992-07-24 AU AU24255/92A patent/AU673499B2/en not_active Ceased
- 1992-07-24 IL IL102640A patent/IL102640A0/xx not_active IP Right Cessation
- 1992-07-24 KR KR1019940700217A patent/KR0137806B1/ko not_active Expired - Fee Related
- 1992-07-24 DK DK92917108T patent/DK0605442T3/da active
- 1992-07-24 SK SK88-94A patent/SK285046B6/sk not_active IP Right Cessation
- 1992-07-24 BR BR9206313A patent/BR9206313A/pt not_active Application Discontinuation
- 1992-07-24 WO PCT/US1992/006194 patent/WO1993002108A1/en active IP Right Grant
- 1992-07-25 MY MYPI92001327A patent/MY121185A/en unknown
- 1992-07-27 AP APAP/P/1992/000413A patent/AP307A/en active
- 1992-07-27 PT PT100735A patent/PT100735B/pt not_active IP Right Cessation
1994
- 1994-01-21 NO NO19940219A patent/NO318097B1/no not_active IP Right Cessation
- 1994-01-24 FI FI940336A patent/FI117703B/fi active IP Right Grant
- 1994-01-24 OA OA60460A patent/OA09879A/en unknown
- 1994-01-24 BG BG98411A patent/BG62656B1/bg unknown
1995
- 1995-06-29 HU HU95P/P00595P patent/HU211881A9/hu unknown

Also Published As

Publication number	Publication date
EP1266965B1 (en)	2006-05-24
PT100735A (pt)	1993-10-29
BR9206313A (pt)	1995-04-11
NO940219L (no)	1994-03-25
JPH06509708A (ja)	1994-11-02
CZ289472B6 (cs)	2002-01-16
MY121185A (en)	2006-01-28
ES2265005T3 (es)	2007-02-01
SK285046B6 (sk)	2006-05-04
AP307A (en)	1994-01-31
BG98411A (bg)	1995-02-28
DE69233011D1 (de)	2003-05-22
WO1993002108A1 (en)	1993-02-04
HU9400201D0 (en)	1994-05-30
EP1715045A3 (en)	2006-12-13
HU211881A9 (en)	1995-12-28
PT100735B (pt)	1999-07-30
EP1715045A2 (en)	2006-10-25
ES2196002T3 (es)	2003-12-16
FI940336A0 (fi)	1994-01-24
JP3048640B2 (ja)	2000-06-05
AU673499B2 (en)	1996-11-14
ATE237638T1 (de)	2003-05-15
EP1266965A2 (en)	2002-12-18
CZ14994A3 (en)	1994-07-13
DE69233628D1 (de)	2006-06-29
SK8894A3 (en)	1994-09-07
NZ243706A (en)	1994-08-26
KR0137806B1 (ko)	1998-04-30
DE69233628T2 (de)	2007-04-26
AU2425592A (en)	1993-02-23
HUT70272A (en)	1995-09-28
IL102640A0 (en)	1993-01-14
DE69233011T2 (de)	2003-11-06
SK285960B6 (sk)	2007-12-06
DK1266965T3 (da)	2006-09-25
EP0605442B1 (en)	2003-04-16
NO318097B1 (no)	2005-01-31
EP0605442A1 (en)	1994-07-13
EP1266965A3 (en)	2003-01-02
FI940336L (fi)	1994-03-10
RO116404B1 (ro)	2001-01-30
CA2114015C (en)	2002-12-10
EP0605442A4 (en)	1995-07-12
AP9200413A0 (en)	1992-07-31
OA09879A (en)	1994-09-15
FI117703B (fi)	2007-01-31
CA2114015A1 (en)	1993-02-04
NO940219D0 (no)	1994-01-21
DK0605442T3 (da)	2003-08-04
ATE327331T1 (de)	2006-06-15

Publication	Publication Date	Title
US5658570A (en)	1997-08-19	Recombinant antibodies for human therapy
KR0137806B1 (ko)	1998-04-30	사람의 질병 치료를 위한 재조합 항체
US5756096A (en)	1998-05-26	Recombinant antibodies for human therapy
JP3619866B2 (ja)	2005-02-16	ヒト治療のための組換え抗ｃｄ４抗体
US7524498B2 (en)	2009-04-28	Human immunomodulatory monoclonal antibodies for the treatment of cancer
IE84118B1 (en)		Recombinant antibodies for human therapy
RU2170256C2 (ru)	2001-07-10	Рекомбинантное антитело, специфичное к cd4, способ его получения и фармацевтическая композиция для лечения псориаза